Kriya Therapeutics has raised $313 million in one of the largest 2025 biopharma funding rounds, boosting its pipeline aimed at one-time gene therapies for chronic diseases including neurologic, metabolic, and ophthalmic conditions. Despite concerns about AAV vectors causing acute liver injury and immune reactions limiting re-dosing, Kriya advances over nine gene therapy candidates. The company’s approach emphasizes innovative viral vector delivery to address intractable diseases, signaling continued momentum in gene therapy development.